Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...

Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa Gilead Sciences, Inc. (Nasdaq: GILD) today ...

Fintel reports that on November 13, 2025, Scotiabank initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Sector Outperform recommendation. Analyst Price Forecast Suggests 3.56% Upside As of ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...

It’s been 20 years since Marilynne Robinson’s Gilead was awarded the Pulitzer Prize. When I first read the novel, I recall how quickly I was pulled into the story by the quiet shock and elegance of ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...

Nicole Taxiltardis of Newtown preps one of her homemade products sold under the Balm of Gilead name. Photo courtesy of Nicole Taxiltardis Clean, nontoxic products are all the buzz in today’s skincare ...

Gilead Sciences broke ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in California. This milestone ...

New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value Gilead Sciences (Nasdaq: GILD) today celebrates the ...